In a regulatory filing to stock exchanges today, Mankind Pharma Ltd, the fourth-largest pharmaceutical company in India by ...

The company, however, did not disclose how it aims to utilise the raised capital. In July this year, Mankind had announced ...

Mankind Pharma has been in focus since the company announced the acquisition of Bharat Serums and Vaccines from Advent ...

Reports indicate that Mankind Pharma plans to issue listed and rated commercial paper, with a face value to be determined as ...

The company will raise up to Rs 5,000 crore through non-convertible debentures (NCDs) maturing in up to 48 months, according ...

Mankind Pharma plans to raise up to Rs 10,000 crore through non-convertible debentures and commercial papers. The board ...

Mankind Pharma's Q1 profit surged 10% YoY to ₹543 crore; brokerage Motilal Oswal expects 14% earnings CAGR over FY24-26 ...

Mankind Pharma will issue non-convertible debentures (NCDs) and commercial papers (CP) worth ₹5,000 crore. These funds will ...

Mankind Pharma Limited's Fund Raising Committee has finalised a comprehensive plan to issue non-convertible debentures (NCDs) and commercial papers (CP) to raise a total of Rs 5,000 crore on Monday.

Mankind Pharma Ltd.’s board approved issuing Non-Convertible Debentures and Commercial Papers to raise up to ₹10,000 Crore, ...

Mankind Pharma on Monday said it will raise up to Rs 10,000 crore via issuance of non-convertible debentures and commercial ...

Mankind Pharma fund raising committee finalised a comprehensive plan to issue non-convertible debentures (NCDs) and ...